JP Morgan Chase’s Serina Therapeutics SER Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-10
Closed -$54 7848
2025
Q3
$54 Buy
10
+1
+11% +$5 ﹤0.01% 7217
2025
Q2
$55 Sell
9
-3
-25% -$17 ﹤0.01% 6891
2025
Q1
$68 Sell
12
-1
-8% -$5 ﹤0.01% 6928
2024
Q4
$65 Hold
13
﹤0.01% 7078
2024
Q3
$87 Buy
13
+2
+18% +$16 ﹤0.01% 7022
2024
Q2
$105 Buy
11
+10
+1,000% +$98 ﹤0.01% 6884
2024
Q1
$13 Sell
1
-57
-98% -$797 ﹤0.01% 7214
2023
Q4
$790 Hold
58
﹤0.01% 6867
2023
Q3
$1.39K Buy
58
+1
+2% +$26 ﹤0.01% 6601
2023
Q2
$1.8K Buy
+57
New +$1.22K ﹤0.01% 6357
2023
Q1
Hold
0
7304
2022
Q4
Hold
0
7069
2022
Q3
Hold
0
6919
2022
Q2
Hold
0
6952
2022
Q1
Hold
0
7090
2021
Q4
Hold
0
7016
2021
Q3
Hold
0
6868
2021
Q2
Hold
0
6659
2021
Q1
Hold
0
6417
2020
Q4
Hold
0
5981
2020
Q3
Sell
-10
Closed -$357 5834
2020
Q2
$0 Sell
10
-981
-99% -$28.9K ﹤0.01% 5750
2020
Q1
$32K Buy
991
+196
+25% +$9.22K ﹤0.01% 4849
2019
Q4
$51K Buy
795
+597
+302% +$32.2K ﹤0.01% 5123
2019
Q3
$14K Buy
198
+32
+19% +$3.04K ﹤0.01% 5463
2019
Q2
$21K Sell
166
-16
-9% -$2.17K ﹤0.01% 5432
2019
Q1
$26K Buy
182
+108
+146% +$15.8K ﹤0.01% 5342
2018
Q4
$8K Buy
+74
New +$9.41K ﹤0.01% 5478

Other funds holding SER

JP Morgan Chase's SER Position: Q4 2025 in Review

JP Morgan Chase sold out of Serina Therapeutics (SER) in Q4 2025, closing a stake of 10 shares — an estimated $54 sold.

JP Morgan Chase first reported a position in SER in Q4 2018 and held it in 17 quarters. The position peaked at $51K in Q4 2019. 22 funds tracked by Wall St. Rank hold SER as of Q4 2025.

  • JP Morgan Chase reported no remaining Serina Therapeutics position as of Q4 2025 after selling out during the quarter.
  • JP Morgan Chase sold 10 Serina Therapeutics shares in Q4 2025, an estimated $54.
  • JP Morgan Chase first reported a position in Serina Therapeutics in Q4 2018 and held it in 17 quarters.
  • JP Morgan Chase's Serina Therapeutics position peaked at $51K in Q4 2019.
  • 22 funds tracked by Wall St. Rank held Serina Therapeutics as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.